Research Papers:

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma

Tengyue Zhang, Kelong Ma, Jin Huang, Shitang Wang, Yabei Liu, Gaofei Fan, Miao Liu, Guangshan Yang, Cheng Wang and Pingsheng Fan _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:110052-110063. https://doi.org/10.18632/oncotarget.22123

Metrics: PDF 1325 views  |   HTML 2607 views  |   ?  


Tengyue Zhang1,2,*, Kelong Ma3,*, Jin Huang2,*, Shitang Wang4,*, Yabei Liu2, Gaofei Fan2, Miao Liu2, Guangshan Yang2, Cheng Wang4 and Pingsheng Fan1,2

1School of Clinical Medicine, Shan Dong University, Jinan 250100, China

2The Cancer Hospital of Anhui Province, Provincial Hospital of Anhui Medical University, Hefei 230032, China

3Clinical College of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230032, China

4Department of General Surgery, Provincial Hospital of Anhui Medical University, Hefei 230032, China

*These authors have contributed equally to this work

Correspondence to:

Pingsheng Fan, email: [email protected]

Cheng Wang, email: [email protected]

Keywords: hepatocellular carcinoma (HCC); verapamil (VER); doxorubicin (ADM); CDKN2B; chemotherapy resistance

Received: June 14, 2017     Accepted: October 05, 2017     Published: October 26, 2017


In this study, we explored the function and mechanism of CDKN2B genes in verapamil (VER)-induced reversal of resistance to doxorubicin (ADM) chemotherapy in hepatocellular carcinoma (HCC). We examined 4 HCC cell lines and found that the expression levels of CDKN2B genes correlated with the level of apoptosis induced by ADM+VER. Overexpression of CDKN2B genes promoted apoptosis in cells treated with VER+ADM. CDKN2B knockdown using siRNA weakened the effect of ADM+VER, indicating that ADM+VER promotes HCC cell apoptosis and that CDKN2B genes participate in VER-mediated promotion in tumor cell apoptosis. Future research will further explore the functional mechanism, and the associated signal transduction pathways via which CDKN2B affects HCC drug resistance.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22123